Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
February 21 2024 - 7:00AM
Immunocore to report fourth quarter and
full year 2023 financial results and host call on February 28,
2024
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
& ROCKVILLE, Md., US, 21 February 2024) Immunocore Holdings plc
(Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage
biotechnology company pioneering and delivering transformative
immunomodulating medicines to radically improve outcomes for
patients with cancer, infectious diseases and autoimmune diseases,
today announced that it will report full year 2023 results, before
the US markets open on Wednesday, February 28, 2024. Following the
announcement, the Company will host a live teleconference and
webcast at 8:00 a.m. ET (1:00 p.m. GMT) to discuss their financial
results and provide a business and portfolio update.
Audio WebcastThe call will be
webcast live and can be accessed by visiting ‘Events’, under ‘News
& Events’, via the ‘Investors’ section of Immunocore’s website
at www.immunocore.com. Following the event, a replay will also be
made available for a limited time.
Conference Call
Details:Domestic (toll-free): 877-405-1239International
(toll): +1 201-389-0851
About
Immunocore Immunocore is a commercial-stage
biotechnology company pioneering the development of a novel class
of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing
monoclonal TCRs Against X disease – designed to treat a broad range
of diseases, including cancer, autoimmune, and infectious disease.
Leveraging its proprietary, flexible, off-the-shelf ImmTAX
platform, Immunocore is developing a deep pipeline in multiple
therapeutic areas, including five clinical stage programs in
oncology and infectious disease, advanced pre-clinical programs in
autoimmune disease and multiple earlier pre-clinical programs. The
Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been
approved for the treatment of HLA-A*02:01-positive adult patients
with unresectable or metastatic uveal melanoma in the United
States, European Union, Canada, Australia, and the United
Kingdom.
CONTACT: Immunocore Sébastien
Desprez, Head of Communications T: +44 (0) 7458030732 E:
sebastien.desprez@immunocore.com Follow
on Twitter: @Immunocore
Investor Relations Clayton Robertson,
Head of Investor Relations T: +1 215-384-4781 E:
ir@immunocore.com
Immunocore (NASDAQ:IMCR)
Historical Stock Chart
From Apr 2024 to May 2024
Immunocore (NASDAQ:IMCR)
Historical Stock Chart
From May 2023 to May 2024